NCT00664027View on ClinicalTrials.gov

Phase IIa Trial to Determine the Effects of Bardoxolone Methyl on Renal Function in Patients With Diabetic Nephropathy

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions

Diabetic Nephropathy

Interventions

DRUG

RTA 402 (Bardoxolone Methyl)

Stratum 1: 25, 75, 150mg/day, orally, 28 consecutive days Stratum 2: 25 mg/day, orally, 28 consecutive days followed by 75 mg/day, orally, 28 consecutive days

Trial Locations (3)

77055

West Houston Clinical Research Services, Houston

78215

Renal Associates, PA, San Antonio

78229

DGD Research, San Antonio